IBEC
Junior Project Manager at the Plataforma ISCIII Biobancos y Biomodelos (Ref.: PM2-NM)
Ref: PM2-NM // Deadline: 18/03/2024
Project Manager at Plataforma ISCIII Biobancos y Biomodelos (Ref.: PM1-NM)
Ref: PM1 // Deadline: 18/03/2023
Research Assistant on Therapy resistance and immune evasion on a novel MNK inhibitor (PPCC-MnkImmunOnco)
Ref: PPCC-MnkImmunOnco/ Deadline: 08/05/2023
Tribute to Josep A. Planell, “much more than the anniversary celebration of a friend, mentor, colleague”
With these words Josep Samitier inaugurated last week the tribute event to Josep A. Planell, one of the founders and first director of IBEC, for a whole life dedicated to … Read more
Bioinspired Interactive Materials and Protocellular Systems
Mastering communication between synthetic or hybrid materials with tissues is one of the grand challenges of contemporary biomedical systems that our society demands. We want to uncover design rules to … Read more
Fiona Watt, member of IBEC’s SAB, appointed as EMBO Director
Fiona Watt, Director of the Centre for Stem Cells & Regenerative Medicine at King’s College London, and member of IBEC´s Scientific Advisory Board (SAB), has been appointed as new Director of the European Molecular Biology Organization (EMBO). The British cell biologist will take up the appointment in early 2022.
IBEC receives a visit from the Mayor of Barcelona interested in our research against Covid19
The Mayor of Barcelona, Ada Colau, visited IBEC facilities last Friday to learn, by our Director and a group of researchers, how bioengineering can help find solutions to health problems such as COVID19, cancer, or degenerative diseases.
The Mayor of Barcelona, Ada Colau, visited IBEC facilities last Friday to learn, by our Director and a group of researchers, how bioengineering can help find solutions to health problems such as COVID19, cancer, or degenerative diseases.When in early 2020, more than 200 scientists gathered in La Pedrera in Barcelona to discuss the present and future of bioengineering, no one imagined that the world would experience the first pandemic of the 21st century and that science would take on more importance than ever.
Researchers at IBEC help identifying a drug in clinical phase that blocks the effects of SARS-Co-V2
IBEC researchers led by ICREA Research Professor Núria Montserrat, together with international collaborators, have identified a drug capable of blocking the effects of the SARS-Co-V2 virus, the origin of the Coronavirus 2019 disease.
IBEC researchers led by ICREA Research Professor Núria Montserrat, together with international collaborators, have identified a drug capable of blocking the effects of the SARS-Co-V2 virus, the origin of the Coronavirus 2019 disease.The treatment, which can be tested on two hundred Covid-19 patients as of today, has proven effective in mini-kidneys generated from human stem cells. Using hese organoids generated by bioengineering techniques, it has been deciphered how SARS-Co-V2 interacts and infects human kidney cells.
IBEC in the catalan TV news
IBEC appears on the catalan news on TV3, where they summarise the various Catalan initiatives to fight against Covid-19.